Über uns

Our whitepaper gives an overview of German oncology data sources for real-world evidence studies – and how to choose the right one.

Population-based ZfKD registry data show that most lung cancers in Germany are still diagnosed at stage IV, with poor survival in advanced disease.

OncoCase analysed claims data from 6.3 million insured persons to track bladder cancer incidence, prevalence and mortality in Germany over the last decade.

Real-world data from two German claims databases show that fewer than half of patients with mUC receive systemic treatment within 12 months.

A comprehensive claims-data analysis shows rising WM incidence and a substantial economic burden – even though most patients start with watch-and-wait.

German claims data describe patients with relapsed/refractory multiple myeloma treated with belamaf – and highlight the importance of ophthalmological monitoring.

A claims-data study shows that CLL prevalence in Germany rose by more than 60% between 2012 and 2022, alongside growing use of BTK inhibitors.

German claims data show that only 28% of intermediate- and high-risk NMIBC patients remain on BCG maintenance at 24 months – and that adherence pays off.

New real-world evidence from German claims data suggests that combining dasatinib with proton pump inhibitors is associated with earlier treatment switching in CML.

In dieser retrospektiven Analyse wurden Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkarzinom (aNSCLC) aus dem Sächsischen Krebsregister untersucht. Von 2015 bis 2019 wurden 4.858 Patienten mit NSCLC im Stadium IIIB, IIIC und IV eingeschlossen. Die häufigsten Pathologien waren Adenokarzinom und Plattenepithelkarzinom.

Prof. Dr. Thomas Wilke und Sabrina Müller aus dem OncoCase-Team haben zusammen mit Klinikern und Gesundheitsökonomen aus Deutschland, USA und Kanada eine multinationale retrospektive Versorgungsforschungsstudie durchgeführt; die Ergebnisse wurden im Februar 2024 veröffentlicht: